Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 11/20 | 0.38 |
| ▸ | GSK3B | P49841 | 11/20 | 0.38 |
| ▸ | WNT1 | P04628 | 5/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17770057 | 1.00 | DYRK1A (0.38) | DYRK1AGSK3BWNT1ABL1CNR2 | |
| SCHEMBL17770061 | 1.00 | DYRK1A (0.38) | DYRK1AGSK3BWNT1ABL1CNR2 | |
| SCHEMBL20720935 | 0.96 | GSK3B (0.37) | DYRK1AGSK3BWNT1ABL1PIK3CD | |
| SCHEMBL17778546 | 0.96 | GSK3B (0.37) | DYRK1AGSK3BWNT1ABL1PIK3CD | |
| SCHEMBL17770272 | 0.92 | MAP3K5 (0.32) | CNR2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17770048 | 0.92 | MAP3K5 (0.32) | CNR2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17770052 | 0.92 | MAP3K5 (0.32) | CNR2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17770276 | 0.92 | MAP3K5 (0.32) | CNR2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL19714017 | 0.89 | RPS6KA3 (0.37) | — | |
| SCHEMBL19714324 | 0.89 | RPS6KA3 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | DYRK1A 2959/4885GSK3B 2340/4885WNT1 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.